Oklo receives DOE approval for Aurora Fuel Fabrication Facility CSDR
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Approval of Safety Design: The U.S. Department of Energy has approved Oklo's Conceptual Safety Design Report for the Aurora Fuel Fabrication Facility at Idaho National Laboratory, marking a significant milestone for the company.
Next Steps in Process: Following this approval, Oklo will proceed with the Preliminary Documented Safety Analysis and later the Documented Safety Analysis as part of the construction process for its first commercial Aurora powerhouse.
Analyst Views on OKLO
Wall Street analysts forecast OKLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKLO is 129.42 USD with a low forecast of 90.00 USD and a high forecast of 175.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
9 Buy
7 Hold
0 Sell
Moderate Buy
Current: 97.600
Low
90.00
Averages
129.42
High
175.00
Current: 97.600
Low
90.00
Averages
129.42
High
175.00
About OKLO
Oklo Inc. is an advanced nuclear technology company. The Company is engaged in developing fast fission power plants to provide clean, reliable, and affordable energy at scale. It is developing advanced fuel recycling technologies in collaboration with the United States Department of Energy and United States National Laboratories. It provides 24/7 clean energy to data centers, factories, industrial sites, communities, and defense facilities. It offers heat and power through power purchase agreements. Its powerhouse product line, Aurora, is designed to be inherently safe, to be able to run on fresh or recycled fuel, and to produce 15-50 megawatts electric (MWe) and with the potential to expand powerhouse size to produce 100 MWe of electricity. The Company intends to develop specialized radioisotope production capabilities to address urgent supply shortages in life-saving medical radioisotopes and advanced industrial applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
